Investors

Media Coverage

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Media Coverage

Trump’s psychedelic drug order boosts investor interest with promise of faster reviews [Reuters]

May 20, 2026

New antidepressants: Tackling treatment resistant depression [LaBiotech]

May 19, 2026

Executive Order For Psychedelics [Clinical Leader]

May 8, 2026

The Neuroplastogen Bet: Inside the Science, the Hype, and the Unanswered Questions in Psychedelic-Inspired Medicine [Meditech Today]

May 6, 2026

Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies [Benzinga]

May 5, 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field [Microdose]

May 5, 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map. [Microdose]

April 27, 2026

Hope For Non-Hallucinogenic Neuroplastogens [Drug Discovery Online]

March 9, 2026

The Patent War That Wasn’t: How Enveric’s Legal Win Reframes the Neuroplastogen Race [Pharma Tech News]

February 25, 2026

Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested [Benzinga]

February 25, 2026

1
2
3
…
17
›